SCHEMBL2010474

SCHEMBL2010474

CCOC(=O)COc1ccc(C(=O)CNC(=O)OC(C)(C)C)c(O)c1CC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP7 P55210 2/20 0.39
CASP3 P42574 1/20 0.39
CASP9 P55211 1/20 0.39
ESR1 P03372 1/20 0.38
GAA P10253 2/20 0.37
MAPK1 P28482 1/20 0.37
ABCB1 P08183 1/20 0.36
ALDH1A1 P00352 3/20 0.35
PPARG P37231 2/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
HPGD P15428 3/20 0.34
KDM4E B2RXH2 2/20 0.34
CASP1 P29466 2/20 0.34
HSD17B10 Q99714 2/20 0.34
LMNA P02545 1/20 0.34
GLA P06280 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013984 0.92 PPARG (0.44) CASP7CASP3CASP9ESR1ABCB1
SCHEMBL2011589 0.89 CASP7 (0.40) CASP7CASP3CASP9ESR1GAA
SCHEMBL2011021 0.88 CASP7 (0.39) CASP7CASP3CASP9ESR1GAA
SCHEMBL2008148 0.88 ALDH1A1 (0.43) CASP7CASP3CASP9ESR1GAA
SCHEMBL2012428 0.82 HPGD (0.45) CASP7CASP3CASP9GAAMAPK1
SCHEMBL2008607 0.81 SYK (0.43) ABCB1PPARGPPARDPPARALMNA
SCHEMBL2011241 0.80 PDE5A (0.43) CASP7CASP3CASP9ESR1GAA
SCHEMBL2012183 0.79 HPGD (0.55) GAAMAPK1ALDH1A1PPARDHPGD
SCHEMBL2012527 0.79 CASP3 (0.45) CASP7CASP3CASP9ESR1GAA
SCHEMBL2014174 0.79 CASP3 (0.45) CASP7CASP3CASP9ESR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 CASP7 4127/4885CASP3 4105/4885CASP9 3233/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 CASP7 4127/4885CASP3 4105/4885CASP9 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.